LOGIN  |  REGISTER
Recursion
Chimerix

Nyxoah: Publication Relating To Transparency Notifications

November 18, 2024 | Last Trade: US$6.43 0.08 1.26

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), November 18, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold. Based on the notification, ResMed Inc. holds 1,727,864 voting rights, representing 4.62% of the total number of voting rights on October 9, 2024 (37,389,015).

The notification dated November 5, 2024 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement:
    • ResMed Inc. (with address at 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA)
  • Date on which the threshold was crossed: October 9, 2024
  • Threshold that is crossed: 5%
  • Denominator: 37,389,015
  • Notified details:
A) Voting rightsPrevious notificationAfter the transaction

 
# of voting rights# of voting rights% of voting rights
Holders of voting rights
 
Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
ResMed Inc.1,619,7561,727,864
 

 

 

 
TOTAL1,727,864 04.62%0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.

Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page